REVELATION BIOSCIENCES, INC.

REVB ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Operating Activities
Net Income $-8.9M $-15.0M $-120.3K $-10.8M $-12.0M $-1.6M $-3.6K
Depreciation & Amortization
Depreciation $27.1K $27.9K $25.0K $25.0K $16.8K
Amortization
Stock-Based Compensation $595.4K $168.9K $155.7K $301.1K $470.9K
Net Cash from Operating Activities $-8.3M $-18.3M $-7.3M $-11.2M $-11.1M $-216.7K
Investing Activities
Capital Expenditures $19.2K $132.0K
Business Acquisitions
Net Cash from Investing Activities $-19.2K $-132.0K $-74.0M
Financing Activities
Dividends Paid
Stock Repurchases $35.5M
Net Cash from Financing Activities $12.5M $12.8M $14.0M $15.2M $8.0M $74.3M
Net Change in Cash $11.7K
Free Cash Flow $-18.3M $-11.2M